Wealthquest Corp Buys New Position in Amedisys, Inc. (NASDAQ:AMED)

Key Points

• Wealthquest Corp has acquired a new stake in Amedisys, Inc., purchasing 13,516 shares worth approximately $1.31 million, as reported in its latest SEC filing.
• Several hedge funds, including Norges Bank and Pentwater Capital Management, have significantly increased their stakes in Amedisys during the fourth quarter, indicating strong institutional interest.
• Amedisys reported earnings of $1.54 per share for the last quarter, exceeding analysts' expectations, with a revenue increase of 5.2% year-over-year amounting to $621.86 million.

Wealthquest Corp acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,516 shares of the health services provider's stock, valued at approximately $1,310,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMED. Alpine Associates Management Inc. lifted its stake in shares of Amedisys by 11.7% during the 1st quarter. Alpine Associates Management Inc. now owns 992,120 shares of the health services provider's stock worth $91,900,000 after purchasing an additional 104,000 shares during the period. Federated Hermes Inc. grew its position in shares of Amedisys by 8.7% in the first quarter. Federated Hermes Inc. now owns 3,101 shares of the health services provider's stock valued at $287,000 after purchasing an additional 247 shares during the period. Meeder Advisory Services Inc. grew its position in shares of Amedisys by 29.3% in the first quarter. Meeder Advisory Services Inc. now owns 3,039 shares of the health services provider's stock valued at $282,000 after purchasing an additional 688 shares during the period. LPL Financial LLC grew its position in shares of Amedisys by 2.0% in the first quarter. LPL Financial LLC now owns 31,336 shares of the health services provider's stock valued at $2,903,000 after purchasing an additional 605 shares during the period. Finally, MRP Capital Investments LLC grew its position in shares of Amedisys by 88.9% in the first quarter. MRP Capital Investments LLC now owns 595 shares of the health services provider's stock valued at $55,000 after purchasing an additional 280 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Trading Down 0.1%

Shares of Amedisys stock traded down $0.09 during trading hours on Friday, reaching $98.51. The stock had a trading volume of 872,139 shares, compared to its average volume of 370,725. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of 38.33, a P/E/G ratio of 1.33 and a beta of 0.89. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $99.00. The company has a current ratio of 1.36, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The firm has a 50 day simple moving average of $96.75 and a two-hundred day simple moving average of $94.17.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 EPS for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The firm had revenue of $621.86 million for the quarter, compared to analyst estimates of $614.61 million. During the same quarter last year, the firm posted $0.98 earnings per share. Amedisys's revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on AMED shares. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.